{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Haemolytic uraemic syndrome"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Pulmonary haemorrhage"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"description":"A DLT was defined as any of the following toxicities assessed by the investigator as possibly, probably, or definitely attributable to carfilzomib, with protocol defined exclusions: Any Grade 4 nonhematologic toxicity, ≥ Grade 4 neutropenia or ≥ Grade 3 thrombocytopenia.","groups":[{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 in combination with R3 IV for approximately 9 weeks (1-week lead-in window, 28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG000","title":"Phase 1b: Dose Escalation 1 (20 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 27 mg/m\\^2 dose in combination with R3 IV for approximately 9 weeks (1-week lead-in window, 28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG001","title":"Phase 1b: Dose Escalation 1 (20/27 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 27 mg/m\\^2 dose in combination with VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG002","title":"Phase 1b: Dose Escalation 2 (20/27 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 36 mg/m\\^2 dose in combination with VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG003","title":"Phase 1b: Dose Escalation 2 (20/36 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 45 mg/m\\^2 dose in combination VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG004","title":"Phase 1b: Dose Escalation 2 (20/45 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 56 mg/m\\^2 dose in combination VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG005","title":"Phase 1b: Dose Escalation 2 (20/56 mg/m^2)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Phase 1b DLT Evaluable Analysis Set: All participants who received all planned dose of carfilzomib and the chemotherapy backbone per protocol during the lead-in window and induction cycle, or received at least one dose of carfilzomib and the chemotherapy backbone per protocol and experienced a DLT prior to completion of the lead-in window or induction cycle, or as clinically indicated.","reportingStatus":"POSTED","timeFrame":"Up to approximately 35 days","title":"Phase 1b: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}